# (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Source: https://onco.cc/trials/nct05208047/  
OnCo record `nct05208047` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Bezuclastinib in gastrointestinal stromal tumour, now recruiting.

## Summary

(Peak) A Phase 3 Randomised Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumours is a phase 3 interventional study registered as NCT05208047, led by Cogent Biosciences, and recruiting on the registry. Official title: A Phase 3 Randomised, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumours. Planned enrolment is 482 participants (estimated). The study started in 2022-04-14 and primary completion was reached in 2025-09-30. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-22
- Tags: ctgov-ingest
- Registry id: NCT05208047
- Phase: 3
- Setting: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects With Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
- Sponsor: Cogent Biosciences
- Enrolled: 482

## Notes

- Registry status on 22 September 2026: Recruiting (registry record last updated 16 June 2026; primary completion reached 30 September 2025).

## Sources

- ClinicalTrials.gov NCT05208047: https://clinicaltrials.gov/study/NCT05208047

## Connected records

- cancers: [Gastrointestinal stromal tumour (GIST)](https://onco.cc/cancers/gist/)
- drugs: [Bezuclastinib](https://onco.cc/drugs/bezuclastinib/)
- companies: [Cogent Biosciences](https://onco.cc/companies/cogent-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct05208047.json